Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of Ontario’s Cancer ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

Colorectal cancer (CRC) is a type of cancer that begins in the colon (large intestine) or rectum, which are parts of the ...

The most important take-home information from the INTERLACE trial is that in some people with cervical cancer that are ...

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder cancer. Using the immunotherapy drug durvalumab before and after surgery ...

The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...

Cancer is a disease of the genome, according to Dr. Elli Papaemmanuil, computational oncologist at MSK. By looking at the ...

Radiotherapy is a cornerstone of cancer care. However, in recent decades, Sweden has fallen behind in this area, both in ...

South Korea’s first domestically developed anti-cancer drug approved by the U.S. Food and Drug Administration (FDA), has ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...